Skip to main content

Praluent Dosage

Generic name: ALIROCUMAB 75mg in 1mL
Dosage form: injection, solution
Drug class: PCSK9 inhibitors

Medically reviewed by Last updated on Apr 25, 2023.

Recommended Dosage

  • In adults with established cardiovascular disease or with primary hyperlipidemia, including HeFH:
    • The recommended starting dose of PRALUENT is either 75 mg once every 2 weeks or 300 mg once every 4 weeks administered subcutaneously [see Dosage and Administration (2.3)].
    • For patients receiving PRALUENT 300 mg every 4 weeks, measure LDL-C just prior to the next scheduled dose, because LDL-C can vary between doses in some patients [see Clinical Studies (14)].
    • If the LDL-C response is inadequate, the dosage may be adjusted 150 mg subcutaneously every 2 weeks.
  • In adults with HeFH undergoing LDL apheresis or in adults with HoFH:
    • The recommended dose of PRALUENT is 150 mg once every 2 weeks administered subcutaneously [see Dosage and Administration (2.3)].
    • PRALUENT can be administered without regard to the timing of LDL apheresis.
  • Assess LDL-C when clinically appropriate. The LDL-lowering effect of PRALUENT may be measured as early as 4 weeks after initiation.

Missed Doses

If a dose is missed:

  • Within 7 days from the missed dose, instruct the patient to administer PRALUENT and resume the patient's original schedule.
  • More than 7 days after the missed dose:
    • For every 2 week dose, instruct the patient to wait until the next dose on the original schedule.
    • For every 4 week dose, instruct the patient to administer the dose and start a new schedule based on this date.

Important Administration Instructions

  • Train patients and/or caregivers on how to prepare and administer PRALUENT, according to the Instructions for Use and instruct them to read and follow the Instructions for Use each time they use PRALUENT.
  • Prior to use, allow PRALUENT to warm to room temperature for 30 to 40 minutes if PRALUENT has been refrigerated [see How Supplied/Storage and Handling (16)].
  • Visually inspect PRALUENT prior to administration. PRALUENT is a clear, colorless to pale yellow solution. Do not use if the solution is cloudy, discolored, or contains particles.
  • Administer PRALUENT subcutaneously into areas of the thigh, abdomen, or upper arm that are not tender, bruised, red, or indurated. Rotate injection sites for each administration.
  • To administer the 300 mg dose, give two 150 mg PRALUENT injections consecutively at two different injection sites.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.